{
    "info": {
        "nct_id": "NCT04877522",
        "official_title": "An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment",
        "inclusion_criteria": "1. Participant with PH+ CML or PH+ ALL currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasatinib), imatinib, nilotinib or bosutinib alone within a Novartis-sponsored study and, in the opinion of the Investigator, would benefit from continued treatment.\n2. Participant has demonstrated compliance on the parent study protocol and is willing and able to comply with scheduled visits, treatment plans and any other study procedures.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
        "exclusion_criteria": "1. Participant has been discontinued from parent study treatment.\n2. Participant currently has unresolved toxicities reported as possibly related to study treatment in the parent study.\n3. Participant's ongoing treatment is currently approved and reimbursed at country level.\n4. Pregnant or nursing (lactating) women.\n5. Women of child-bearing potential, unless they are using highly effective methods of contraception and willing to continue while taking study treatment.\n6. Sexually active males receiving imatinib, nilotinib, bosutinib or dasatinib unwilling to follow the relevant contraception requirements in the local prescribing information.\n7. Applicable for participants on bosutinib treatment at the end of the CABL001A2301 and on other TKIs for CABL001A2202 study that switch to asciminib treatment:\n\n   * Asymptomatic (grade 2) pancreatitis if not resolved within 28 days\n   * QTcF>480msec or inability to determine QTc interval\n   * any grade 3 or 4 toxicity not resolved to grade 2 or lower within 28 days before starting asciminib treatment\n\nOther protocol-defined Inclusion/Exclusion criteria may apply.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participant has demonstrated compliance on the parent study protocol and is willing and able to comply with scheduled visits, treatment plans and any other study procedures.",
            "criterions": [
                {
                    "exact_snippets": "Participant has demonstrated compliance on the parent study protocol",
                    "criterion": "compliance on the parent study protocol",
                    "requirements": [
                        {
                            "requirement_type": "demonstrated",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing and able to comply with scheduled visits, treatment plans and any other study procedures",
                    "criterion": "ability and willingness to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 100 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 100 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participant with PH+ CML or PH+ ALL currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasatinib), imatinib, nilotinib or bosutinib alone within a Novartis-sponsored study and, in the opinion of the Investigator, would benefit from continued treatment.",
            "criterions": [
                {
                    "exact_snippets": "Participant with PH+ CML or PH+ ALL",
                    "criterion": "disease diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "PH+ CML",
                                "PH+ ALL"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasatinib), imatinib, nilotinib or bosutinib alone",
                    "criterion": "current treatment regimen",
                    "requirements": [
                        {
                            "requirement_type": "current medication",
                            "expected_value": [
                                "asciminib (single agent or in combination with imatinib, nilotinib or dasatinib)",
                                "imatinib",
                                "nilotinib",
                                "bosutinib"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "within a Novartis-sponsored study",
                    "criterion": "participation in Novartis-sponsored study",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the Investigator, would benefit from continued treatment",
                    "criterion": "investigator assessment of benefit",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion of benefit",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* QTcF>480msec or inability to determine QTc interval",
            "criterions": [
                {
                    "exact_snippets": "QTcF>480msec",
                    "criterion": "QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "inability to determine QTc interval",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "determinability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Asymptomatic (grade 2) pancreatitis if not resolved within 28 days",
            "criterions": [
                {
                    "exact_snippets": "Asymptomatic (grade 2) pancreatitis",
                    "criterion": "pancreatitis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "grade 2"
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "if not resolved within 28 days",
                    "criterion": "pancreatitis resolution",
                    "requirements": [
                        {
                            "requirement_type": "resolution_time",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Women of child-bearing potential, unless they are using highly effective methods of contraception and willing to continue while taking study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive_potential",
                            "expected_value": "child-bearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless they are using highly effective methods of contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method_effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "usage",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to continue while taking study treatment",
                    "criterion": "contraception use during study treatment",
                    "requirements": [
                        {
                            "requirement_type": "willingness to continue",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Other protocol-defined Inclusion/Exclusion criteria may apply.",
            "criterions": [
                {
                    "exact_snippets": "Other protocol-defined Inclusion/Exclusion criteria may apply.",
                    "criterion": "other protocol-defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Pregnant or nursing (lactating) women.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing (lactating) women",
                    "criterion": "nursing (lactating) status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participant has been discontinued from parent study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Participant has been discontinued from parent study treatment",
                    "criterion": "discontinuation from parent study treatment",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "discontinued"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participant currently has unresolved toxicities reported as possibly related to study treatment in the parent study.",
            "criterions": [
                {
                    "exact_snippets": "Participant currently has unresolved toxicities reported as possibly related to study treatment in the parent study.",
                    "criterion": "toxicities related to study treatment in the parent study",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "unresolved"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Participant's ongoing treatment is currently approved and reimbursed at country level.",
            "criterions": [
                {
                    "exact_snippets": "Participant's ongoing treatment is currently approved",
                    "criterion": "ongoing treatment",
                    "requirements": [
                        {
                            "requirement_type": "approval status",
                            "expected_value": "approved"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participant's ongoing treatment is currently ... reimbursed at country level",
                    "criterion": "ongoing treatment",
                    "requirements": [
                        {
                            "requirement_type": "reimbursement status",
                            "expected_value": "reimbursed at country level"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Sexually active males receiving imatinib, nilotinib, bosutinib or dasatinib unwilling to follow the relevant contraception requirements in the local prescribing information.",
            "criterions": [
                {
                    "exact_snippets": "Sexually active males",
                    "criterion": "sexually active male",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        },
                        {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving imatinib, nilotinib, bosutinib or dasatinib",
                    "criterion": "receiving specific tyrosine kinase inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "medication",
                            "expected_value": [
                                "imatinib",
                                "nilotinib",
                                "bosutinib",
                                "dasatinib"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to follow the relevant contraception requirements in the local prescribing information",
                    "criterion": "willingness to follow contraception requirements",
                    "requirements": [
                        {
                            "requirement_type": "willingness to follow contraception requirements",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* any grade 3 or 4 toxicity not resolved to grade 2 or lower within 28 days before starting asciminib treatment",
            "criterions": [
                {
                    "exact_snippets": "any grade 3 or 4 toxicity not resolved to grade 2 or lower within 28 days before starting asciminib treatment",
                    "criterion": "toxicity",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "resolution",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "resolution_time",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Applicable for participants on bosutinib treatment at the end of the CABL001A2301 and on other TKIs for CABL001A2202 study that switch to asciminib treatment:",
            "criterions": [
                {
                    "exact_snippets": "participants on bosutinib treatment at the end of the CABL001A2301",
                    "criterion": "bosutinib treatment at the end of the CABL001A2301",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "on bosutinib at end of CABL001A2301"
                        }
                    ]
                },
                {
                    "exact_snippets": "on other TKIs for CABL001A2202 study that switch to asciminib treatment",
                    "criterion": "other TKI treatment for CABL001A2202 study and switch to asciminib",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "on other TKIs for CABL001A2202"
                        },
                        {
                            "requirement_type": "treatment switch",
                            "expected_value": "switch to asciminib"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}